VivoSim Labs, Inc.

Multi-year research partnership (2015) for access to exVive3D Human Liver Tissue service and collaboration on 3D bioprinted tissue models for drug discovery

Johnson & Johnson / Janssen Research & Development

NYSE:JNJ

Historic collaboration (2014) to evaluate 3D bioprinted human tissue for drug discovery applications

L'Oréal USA

EPA:OR

Research partnership (2015) to develop 3D bioprinted skin tissue for cosmetic product testing

JCBio Co., Ltd.

Authorized distributor for NAMKind™ toxicology services in South Korea (signed January 2026)

대체 기업

분석에서 대표로 사용하는 상장 비교 기업 및 모니터링 종목.

대체 기업

BICO Group AB (formerly CELLINK)

Merck KGaA

Lonza Group AG

BICO Group AB (formerly CELLINK)

STO:BICO

Swedish publicly traded 3D bioprinting and lab automation company — closest listed peer in 3D bioprinting space. BICO provides bioprinters, bio-inks, and cell culture solutions. Former licensing and legal dispute counterparty with Organovo.

3D Systems Corporation

NYSE:DDD

Larger publicly traded 3D printing company with bioprinting segment exposure. Participates in the broader 3D bioprinting market where VivoSim competes.

Merck KGaA

XETRA:MRK

German science & technology company that is both a supplier (life science reagents) and former customer (research partnership) of Organovo. Listed as a player in the 3D bioprinting market.

Lonza Group AG

SWX:LONN

Swiss CDMO and bioscience solutions provider that had a supply agreement with Organovo's Samsara Sciences subsidiary for cell product distribution. Proxy for the cell & gene therapy supply chain.

지역

공급망을 왜곡할 수 있는 지역별 노출.

지역

United States

South Korea

China

Eli Lilly and Company

JCBio Co., Ltd.

Tekon Biotech (Shanghai) Ltd.

United States

HQ and primary R&D operations; regulatory exposure to FDA policy shift toward New Approach Methodologies (NAMs) replacing animal testing

Eli Lilly and CompanyNYSE:LLYFXR program acquirer and potential NAMKind service customer

South Korea

New market expansion via distributor JCBio; emerging market for NAMKind toxicology services

JCBio Co., Ltd.Authorized distributor in Korea

China

New market expansion via distributor Tekon Biotech; geopolitical and IP risks in Chinese life sciences market

Tekon Biotech (Shanghai) Ltd.Authorized distributor in China

Europe

Historical partnerships with Merck KGaA (Germany) and L'Oréal (France); potential future market for NAMKind services via distributors

Merck KGaAXETRA:MRKMulti-year research partnership

L'Oréal USAEPA:ORResearch partnership for 3D bioprinted skin

집중도

공급망을 왜곡할 수 있는 고객, 공급업체 또는 파트너 집중 노출.

Customer

Critical

Extreme revenue concentration — VIVS has ~$144K annual revenue with no single disclosed commercial customer generating significant, recurring service revenue. The FXR sale to Eli Lilly was a one-time asset sale, not recurring service revenue. Dependency on few large pharma relationships for future growth.

Other

Critical

Going concern risk — VIVS has a market cap of ~$3-4M, minimal revenue, and has disclosed substantial doubt about its ability to continue as a going concern. The company is reliant on additional financing or partnership revenues.

Other

High

Technology concentration — Dependency on the internally developed NovoGen MMX Bioprinter platform and NovoGel Bio-Ink. Any failure in bioprinting IP, patent challenges, or manufacturing issues would halt all operations.

매출 구성

대상 기업의 매출 구성이 공급망 영향력과 의존도로 이어지는 방식.

NAMKind™ Toxicology Services (3D Liver & Intestine Tissue Models)

100.0%

$0.0B

Primary revenue driver post-rebranding. Demand for these services drives upstream need for primary human cells, bio-inks, bioprinting consumables, and cell culture materials. Customers are pharmaceutical and biotech companies conducting preclinical drug safety testing.

회사 소개개인정보 처리방침서비스 약관면책 조항종목 디렉터리ETF지수13F 보유 종목목표주가무료 도구기술 지도Slack 참여하기

Plutux는 투자자문업자가 아닙니다. 시장 데이터와 AI가 생성한 분석은 정보 제공 및 교육 목적일 뿐 투자 자문이 아닙니다. 면책 조항

VivoSim Labs, Inc.

VIVS 공급망

상류

ZenBio, Inc. (now part of BioIVT)

Corning Incorporated

Lonza Group AG (Bioscience Solutions division)

MTF Biologics / IIAM (International Institute for the Advancement of Medicine)

Thermo Fisher Scientific Inc.

Merck KGaA (Life Science division / MilliporeSigma)

하류

Eli Lilly and Company

Merck KGaA (Darmstadt, Germany)

Johnson & Johnson / Janssen Research & Development

L'Oréal USA

JCBio Co., Ltd.

Tekon Biotech (Shanghai) Ltd.

Yale School of Medicine

대체 기업

BICO Group AB (formerly CELLINK)

3D Systems Corporation

Merck KGaA

Lonza Group AG

지역

United States

South Korea

China

View More

VIVS 공급망

상류

ZenBio, Inc. (now part of BioIVT)

Corning Incorporated

Lonza Group AG (Bioscience Solutions division)

MTF Biologics / IIAM (International Institute for the Advancement of Medicine)

Thermo Fisher Scientific Inc.

Merck KGaA (Life Science division / MilliporeSigma)

하류

Eli Lilly and Company

Merck KGaA (Darmstadt, Germany)

Johnson & Johnson / Janssen Research & Development

L'Oréal USA

JCBio Co., Ltd.

Tekon Biotech (Shanghai) Ltd.

Yale School of Medicine

대체 기업

BICO Group AB (formerly CELLINK)

3D Systems Corporation

Merck KGaA

Lonza Group AG

지역

United States

South Korea

China

View More